Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | TP53 R175H |
Therapy | Alvespimycin + Vorinostat |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 R175H | Advanced Solid Tumor | sensitive | Alvespimycin + Vorinostat | Preclinical | Actionable | In a preclinical study, Alvespimycin (17-DMAG) and Zolinza (vorinostat) extended survival by 59% in mice with tumors expressing Tp53 R172H (which corresponds to R175H in the human Tp53 protein) (PMID: 26009011). | 26009011 |
PubMed Id | Reference Title | Details |
---|---|---|
(26009011) | Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment. | Full reference... |